( EuronextParis:SAN,NYSE:SNY )

News from Sanofi A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jul 12, 2016, 07:00 ET Award-Winning Chef Elizabeth Falkner Reveals Her Struggle with Atopic Dermatitis to Highlight the Physical and Psychological Impact of the Disease

 Celebrity chef, restaurateur, and media personality Elizabeth Falkner has teamed up with Sanofi Genzyme, Regeneron Pharmaceuticals, Inc., the...


Jul 12, 2016, 07:00 ET Award-Winning Chef Elizabeth Falkner Reveals Her Struggle with Atopic Dermatitis to Highlight the Physical and Psychological Impact of the Disease

 Celebrity chef, restaurateur, and media personality Elizabeth Falkner has teamed up with Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN),...


Jun 12, 2016, 15:54 ET Sanofi Announces Positive Phase 3 Results for Investigational Titratable Fixed-Ratio Combination of Insulin Glargine and Lixisenatide

 Sanofi announced today the presentation of the results of the pivotal Phase 3 LixiLan-O and LixiLan-L clinical trials with the investigational...


Jun 11, 2016, 11:01 ET Successful Switch to Sanofi's Toujeo® Evaluated in a Real-World Setting

 Sanofi announced today the release of the new real world data assessing the use of Toujeo® (insulin glargine injection 300 Units/mL). The...


Jun 06, 2016, 01:00 ET Regeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a one-year Phase 3 study, known as LIBERTY AD CHRONOS,...


May 25, 2016, 18:50 ET FDA Advisory Committee Recommends Approval of Sanofi Treatment for Adults with Type 2 Diabetes

 Sanofi announced today that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA)...


Apr 29, 2016, 07:37 ET Solid Performance in the First Quarter of 2016 with Business EPS up 5.3% at Constant Exchange Rates

 Sanofi (NYSE: SNY; EURONEXT: SAN) Experience the interactive Multimedia News Release here:...


Apr 29, 2016, 05:07 ET Sanofi Q1 2016 Results

Sanofi, a global and diversified healthcare leader, reports results for the first quarter of 2016. Jérôme Contamine,...


Apr 29, 2016, 04:54 ET Sanofi - Résultats T1 2016

Interview de Jérôme Contamine, Directeur Financier Sanofi, leader mondial et diversifié de la santé, publie ses...


Apr 27, 2016, 12:18 ET Sanofi US Collaborates with Duke University and Massachusetts General Hospital on Big Data and Type 2 Diabetes

Sanofi US announced today collaborations with the Duke Clinical Research Institute (DCRI) and, separately, with the Center for Assessment...


Apr 07, 2016, 10:30 ET Sanofi Genzyme Donates Corporate Archives To Harvard Business School

Harvard Business School (HBS) announced today that Cambridge, Mass.-based Sanofi Genzyme, the largest biotechnology company in the state and an...


Apr 01, 2016, 01:00 ET Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that two placebo-controlled Phase 3 studies evaluating...


Mar 16, 2016, 12:30 ET Regeneron and Sanofi Strongly Disagree with U.S. Jury Verdict in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection and Will Appeal

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the companies strongly disagree with a U.S. District Court jury...


Feb 23, 2016, 16:05 ET Sanofi US to Return Auvi-Q® (epinephrine injection, USP) Rights to kaléo

 Sanofi announced today that the license and development agreement between Sanofi and kaléo, formerly Intelliject Inc., the developer of...


Feb 22, 2016, 08:00 ET FDA Accepts Sanofi New Drug Application for Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide

 Sanofi announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for its investigational...


Feb 09, 2016, 08:05 ET Sanofi Delivered 2015 Business EPS up 8.5% on a Reported Basis and Stable at Constant Exchange Rates Consistent with Guidance

 Sanofi (NYSE: SNY; EURONEXT: SAN) Q4 2015 Change Change (CER) 2015 Change Change (CER) Aggregate Group...


Feb 09, 2016, 02:14 ET Sanofi - Résultats 2015

Interview de Olivier Brandicourt, Directeur Général Sanofi, un leader mondial et diversifié de la santé, publie ses...


Feb 09, 2016, 02:12 ET Sanofi - Full Year 2015 Results

Sanofi, a global and diversified healthcare leader, reports annual results for 2015. CEO Olivier Brandicourt comments on results and...


Feb 01, 2016, 08:00 ET Merial Appoints Susan Sholtis as President, North America

 Merial, the animal health division of Sanofi, today announced the appointment of Susan Sholtis as President of its North American...


Jan 20, 2016, 16:32 ET Harwood Feffer LLP Announces Investigation of MannKind Corporation

 Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of MannKind Corporation ("Mannkind" or the...


Jan 08, 2016, 01:00 ET Regeneron and Sanofi Announce Sarilumab Biologics License Application Accepted for Review by US FDA

 Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the...


Jan 05, 2016, 09:00 ET Global Genomics Group (G3) Partners with Sanofi to Identify New Signaling Pathways in Atherosclerotic Cardiovascular Diseases

Global Genomics Group ("G3") announced that it has entered into a research collaboration with Sanofi (EURONEXT: SAN; NYSE: SNY) to identify new...


Dec 23, 2015, 08:00 ET Sanofi Submits New Drug Application for the Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide

 Sanofi announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its...


Dec 23, 2015, 08:00 ET Sanofi Submits New Drug Application for the Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide

 Sanofi announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its...


Dec 11, 2015, 01:00 ET Sanofi and Regeneron Announce UnitedHealth Group Selects Praluent® (alirocumab) Injection for Preferred Access

 Sanofi and Regeneron Pharmaceuticals, Inc. today announced that UnitedHealth Group will provide preferred access to Praluent®...